Biomarkers for the evaluation of valvular aortic stenosis;Biomarker zur abschätzung des schweregrades der aortenklappenstenose

Herz

Volumn 31, Issue 7, 2006, Pages 658-663

  Weber, Michael ^a   Hamm, Christian ^a  

^a KERCKHOFF HEART CENTER   (Germany)

Author keywords

Aortic stenosis; Aortic valve disease; Aortic valve replacement; B type natriuretic peptide; Natriuretic peptide

Indexed keywords

NATRIURETIC FACTOR;

AORTA VALVE STENOSIS; ARTICLE; CONSERVATIVE TREATMENT; DISEASE COURSE; DISEASE SEVERITY; HUMAN; LONGITUDINAL STUDY; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

AORTIC VALVE; AORTIC VALVE STENOSIS; BIOLOGICAL MARKERS; FOLLOW-UP STUDIES; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; KAPLAN-MEIERS ESTIMATE; LONGITUDINAL STUDIES; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 33750541501     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-006-2880-0     Document Type: Article

References (15)

1. Bonow R, Carabello B, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006;48:e1-148 (http://www. acc.org/clinical/guidelines/valvular/index.pdf).
2. Pellikka PA, Sarano ME, Nishimura RA, et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation 2005;111:3290-5.
3. Rosenhek R, Klaar U, Schemper M, et al. Mild and moderate aortic stenosis. Natural history and risk stratification by echocardiography. Eur Heart J 2004;25:199-205.
4. Otto CM. Aortic stenosis: even mild disease is significant. Eur Heart J 2004;25:185-7.
5. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006;92:843-9.
6. Struthers AD. Introducing a new role for BNP: as a general indicator of cardiac structural disease rather than a specific indicator of systolic dysfunction only. Heart 2002;87:97-8.
7. Wasywich CA, Webster MW, Richards AM, et al. Coronary sinus and ascending aortic levels of aldosterone, angiotensin II, and B-type natriuretic peptide in patients with aortic stenosis and in patients with coronary heart disease. Am J Cardiol 2006;97:1068-72.
8. Kupari M, Turto H, Lommi J, et al. Transcardiac gradients of N-terminal B-type natriuretic peptide in aortic valve stenosis. Eur J Heart Fail 2005;7:809-14.
9. Gerber IL, Stewart RA, Legget ME, et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 2003;107:1884-90.
10. Weber M, Arnold R, Rau M, et al. Relation of N-terminal pro-B-type natriuretic peptide to severity of valvular aortic stenosis. Am J Cardiol 2004;94:740-5.
11. Weber M, Arnold R, Rau M, et al. Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur Heart J 2005;26:1023-30.
12. Gerber IL, Legget ME, West TM, et al. Usefulness of serial measurement of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deterioration. Am J Cardiol 2005;95:898-901.
13. Bergler-Klein J, Klaar LJ, Heger M, et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 2004;109:2302-8.
14. Lim P, Monin JL, Monchi M, et al. Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: role of B-type natriuretic peptide. Eur Heart J 2004;25:2048-53.
15. Weber M, Hausen M, Arnold R, et al. The prognostic value of N-terminal pro B-type natriuretic peptide (NT-proBNP) for conservatively and surgically treated patients with aortic valve stenosis. Heart 2006: in press (Epub 2006 Jun 01)